Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its holdings in Charles River Laboratories Intl. Inc (NYSE:CRL) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 75,229 shares of the medical research company’s stock after selling 1,651 shares during the period. Russell Investments Group Ltd. owned 0.15% of Charles River Laboratories Intl. worth $9,968,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of CRL. Texas Permanent School Fund lifted its holdings in Charles River Laboratories Intl. by 0.4% in the 3rd quarter. Texas Permanent School Fund now owns 33,220 shares of the medical research company’s stock worth $4,397,000 after buying an additional 132 shares in the last quarter. Comerica Bank lifted its holdings in Charles River Laboratories Intl. by 3.3% in the 3rd quarter. Comerica Bank now owns 36,103 shares of the medical research company’s stock worth $4,607,000 after buying an additional 1,156 shares in the last quarter. California Public Employees Retirement System lifted its holdings in Charles River Laboratories Intl. by 45.9% in the 3rd quarter. California Public Employees Retirement System now owns 111,416 shares of the medical research company’s stock worth $14,748,000 after buying an additional 35,030 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter valued at about $33,000. Finally, State of Tennessee Treasury Department raised its stake in shares of Charles River Laboratories Intl. by 173.4% in the 3rd quarter. State of Tennessee Treasury Department now owns 49,948 shares of the medical research company’s stock valued at $6,612,000 after purchasing an additional 31,676 shares in the last quarter. Institutional investors own 94.45% of the company’s stock.

A number of equities research analysts have recently issued reports on CRL shares. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. Credit Suisse Group set a $138.00 target price on shares of Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Friday, September 13th. UBS Group cut their target price on shares of Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. SunTrust Banks upped their target price on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and an average price target of $150.50.

Shares of Charles River Laboratories Intl. stock opened at $137.12 on Thursday. The firm has a market cap of $6.45 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 2.02 and a beta of 1.08. Charles River Laboratories Intl. Inc has a 1 year low of $103.00 and a 1 year high of $149.07. The firm’s 50-day simple moving average is $131.70 and its 200-day simple moving average is $133.36. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.20 and a current ratio of 1.43.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.05. The firm had revenue of $668.00 million for the quarter, compared to analyst estimates of $674.08 million. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. Charles River Laboratories Intl.’s quarterly revenue was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.53 earnings per share. On average, equities analysts predict that Charles River Laboratories Intl. Inc will post 6.55 earnings per share for the current year.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: What does a hold rating mean?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.